



02-28, 05

[Handwritten signature]

Docket 17549 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Patrick M. Hughes, et al.,)	Examiner:
)	
Serial Number: 10/617,468)	
)	Art Unit: 1614
Filed: July 10, 2003)	
)	Confirmation No. 3251
For: DELIVERY OF AN ACTIVE DRUG)	
TO THE POSTERIOR PART OF)	
THE EYE VIA SUBCONJUNCTIVAL)	
OR PERIOULAR DELIVERY)	
OF A PRODRUG)	
<hr/>		Irvine, California


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants provide with regard to the above-identified patent application entitled DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOULAR DELIVERY OF A PRODRUG, one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 3 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material



Serial No. 10/617,468

Docket 17549 (AP)

documents or information exists. These documents were disclosed in a Written Opinion in the foreign counterpart of the above-identified application, and were received less than three (3) months ago. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: February 24, 2005

Brent A. Johnson
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date February 24, 2005 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV 295 681 718 US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date February 24, 2005


Adriane Giberson

Name of person mailing paper

Signature of person signing paper

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17549 (AP)	SERIAL NO.: 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCCULAR DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	GROUP: 1614



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,384,333	01/24/1995	DAVIS et al.	514	772.3	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	WO 96/38133	12/05/1996	PCT	A61K	9/14	Y
	BB	WO 00/03660	07/16/1999	PCT	A61K	2/02	Y
	BC	WO 02/087586	04/26/2002	PCT	A61K	31/513	Y
	BD						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Khoobehi, Bahram, et al., <i>Clearance of Fluorescein Incorporated Into Microspheres From the Cornea and Aqueous After Subconjunctival Injection</i> , Ophthalmic Surgery, December 1990, Vol. 21, No. 12, pp. 840-844
	CB	Kompella, Uday, et al., <i>Subconjunctival Nano- and Microparticles Sustain Retinal Delivery of Budesonide, a Corticosteroid Capable of Inhibiting VEGF Expression</i> , IOVS, March 2003, Vol. 44, No. 3, pp. 1192-1200
	CC	Lallemand, F., et al., <i>Cyclosporine A delivery to the eye: A pharmaceutical challenge</i> , Eur. J. Pharm & Biopharm, 56 (2003), pp. 307-318
	CD	de Rojas-Silva, M.-V., et al., <i>Efficacy of subconjunctival cyclosporine-containing microspheres on keratoplasty rejection in the rabbit</i> , Graefe's Arch Clin Exp Ophthalmol (1999) 237, pp. 840-847
	CE	Saishin, Y., et al., <i>Periocular Injection of Microspheres Containing PKC412 Inhibits Choroidal Neovascularization in a Porcine Model</i> , IOVS, November 2003, Vol. 44, No. 11, pp. 4989-4993
	CF	
	CG	
	CH	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.